Acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) are cancers of the blood and bone marrow.
In AML, the bone marrow makes too many myeloblasts, red blood cells, and platelets. Myeloblasts are a type of white blood cell.
In ALL, the bone marrow makes too many lymphocytes, which are another type of white blood cell.
This article outlines the difference between AML and ALL, as well as their associated risk factors and symptoms. It also provides information about diagnosis, treatment, and survival rates.
AML and ALL are both cancers of the blood and bone marrow.
The main difference between the two is that AML affects the production of myeloblasts, red blood cells, and platelets, whereas ALL mainly affects the production of lymphocytes.
Myeloblasts are a type of precursor white blood cell that mature into either neutrophils, basophils, or eosinophils. These types of white blood cell engulf and dissolve different pathogens, such as bacteria and viruses.
Lymphocytes are another type of white blood cell. There are two main types: B lymphocytes and T lymphocytes.
B lymphocytes produce antibodies, whereas T lymphocytes help kill tumor cells and regulate the immune response.
Certain factors can increase a persons risk of developing either AML or ALL. Below, we outline some of the risk factors experts associate with each of these conditions.
AML risk factors include:
ALL is more common in the following groups of people:
Other risk factors for ALL include:
Both ALL and AML are very serious conditions that develop rapidly.
According to a 2021 review, AML is the most common type of leukemia among adults, accounting for around 80% of all cases.
Authors of the review observe that age plays an important role in survival rates for AML. Following treatment, around 15% of people above the age of 60 years will recover, compared with 40% of people below the age of 60 years.
According to another 2021 review, ALL is most common among children aged 210 years. People who are younger than 30 years of age are more likely to experience successful treatment than those who are older. Also, around 30% of adults with ALL fully recover.
AML and ALL are both acute types of leukemia, and their symptoms are similar.
Generally, symptoms of AML and ALL include:
Many of these symptoms overlap with other, less serious conditions. However, anyone who is concerned about symptoms should consult a doctor, especially if they are experiencing a cluster of symptoms.
Symptoms of AML and ALL are similar, and therefore doctors need to perform several tests and physical exams before reaching a diagnosis.
To diagnose AML, a doctor will first request a blood smear test to check for abnormalities in the red and white blood cells, and platelets. They may then request a bone marrow biopsy to check for abnormal cells in the bone marrow.
If these tests indicate AML, the doctor may then order cytometry and cytogenetic tests to determine the type of AML a person has.
Cytometry assesses characteristics of cells, such as:
Cytogenetic tests assess changes to chromosomes within a sample. This may include:
If a person is presenting with symptoms of ALL, a doctor will request a complete blood count to check the numbers of different blood cells in the blood. They will also measure levels of electrolytes and urea in the blood.
A doctor may also request imaging scans of the abdomen and pelvis to help determine the stage of the cancer.
In some cases, a doctor may be concerned that the cancer has spread to the central nervous system. A person may then receive a lumbar puncture to check for the presence of lymphoblasts in their spinal fluid.
Treatment options for AML and ALL are similar.
In both instances, a person will usually receive induction therapy. This is the first-line treatment that aims to put the disease into remission. It typically consists of chemotherapy.
If a person goes into remission after induction therapy, they will begin consolidation therapy. This is the next stage of treatment that kills off any remaining cancer cells in the body in order to help maintain disease remission.
Consolidation therapy for AML may consist of high-dose chemotherapy, hematopoietic cell transplantation (HCT), or both.
HCT involves transplanting the abnormal blood-forming stem cells with healthy blood-forming stem cells from the persons own body or from a donor.
Consolidation therapy for ALL typically consists of multidrug chemotherapy.
In some cases, a doctor may recommend stem cell therapy (SCT). Like HCT, SCT involves replacing the abnormal blood-forming stem cells with healthy ones either from the persons own body or from a donor.
Due to improvements in chemotherapy treatment, SCT for ALL is becoming less common.
People with leukemia may also receive other types of treatment, such as:
The types of additional treatment a person receives will depend on several factors, including:
Below, we outline the relative survival rates for AML and ALL.
A relative survival rate helps give an idea of how long a person with a particular condition will live after receiving a diagnosis compared with those without the condition.
For example, if the 5-year relative survival rate is 70%, it means that a person with the condition is 70% as likely to live for 5 years as someone without the condition.
It is important to remember that these figures are estimates. A person can consult a healthcare professional about how their condition is going to affect them.
According to the National Cancer Institute (NCI), between the years 2011 and 2017, the 5-year relative survival rate for AML in the United States was 29.5%.
This means that 29.5% of people in the U.S. who received an AML diagnosis went on to live 5 years or longer following their initial diagnosis.
Between 2016 and 2018, the lifetime risk of developing AML was 0.5%. The NCI estimates that, during the same time frame, 66,988 people were living with the condition.
The 5-year relative survival rate for ALL is 69.9%.
Between 2016 and 2018, the lifetime risk of developing ALL was 0.1%. According to the NCI estimates, during the same time frame, 103,536 people were living with ALL.
A person who has recently received a diagnosis of AML or ALL may want to find out more about their condition and its treatment.
Below are some questions individuals may want to ask a doctor or wider medical team:
Both AML and ALL are acute types of leukemia. AML causes the body to produce too many myeloblasts, platelets, and red blood cells. By contrast, ALL increases the production of lymphocytes.
Also, both AML and ALL are acute leukemias, and therefore both have similar symptoms. These may include flu-like symptoms, weakness, and fatigue.
Typically, the first-line treatment for both AML and ALL is chemotherapy, which aims to put the disease into remission. Follow-up consolidation therapy can help destroy any remaining cancer cells and maintain remission.
A person can ask a doctor for specific information on the type of leukemia they have and the treatment options available to them.
Continued here:
AML vs. ALL: Differences in symptoms, diagnosis, and survival - Medical News Today
- SUM Hospital conducts Odishas first stem cell transplantation - The Times of India - April 24th, 2024
- Cancer treatment: What is stem cell therapy, and how does it work? - Moneycontrol - April 24th, 2024
- The murky, unregulated world of anti-ageing stem cell therapy - The Telegraph - April 24th, 2024
- Drug Prototype Promising in Treatment of Pulmonary Disease - Medscape - April 20th, 2024
- Man Paralyzed In Surfing Accident Regains Ability to Walk After Stem Cell Treatment - The Inertia - April 20th, 2024
- Medical breakthrough: 8-year-old boy first in New York to receive FDA-approved gene therapy for rare inherited blood disorder - WABC-TV - April 20th, 2024
- Stem Cell Treatment Helped A Man Who Was Paralyzed From The Neck Down To Stand On His Own - Bored Panda - April 20th, 2024
- UM, CUHK jointly hold symposium on stem cells and regenerative medicine - gcs.gov.mo - April 20th, 2024
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
Recent Comments